Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden, Germany, to translate condensate biology into treatments for the toughest diseases.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $227M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Innovation... | innovation... |
| 07.02.2022 | 3E Biovent... | 3ebiovc.co... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2022 | Series C | $150M | - |
| 29.09.2020 | Series B | $77M | - |
Mentions in press and media 8
| Date | Title | Description |
| 12.12.2024 | Dewpoint Therapeutics and ConcertAI Announce the First Phase of their Translational Oncology Partnership | BOSTON and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186. Numerous tu... |
| 04.02.2022 | Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing | - |
| 03.02.2022 | Dewpoint Therapeutics Completes $150M Series C Financing | Dewpoint Therapeutics, Inc., a Boston, MA-based biomolecular condensates company, completed a $150m Series C financing. The round was led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Biove... |
| 06.01.2021 | Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy | |
| 29.09.2020 | Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates | |
| 29.09.2020 | Dewpoint Therapeutics to put 'pedal to the metal' with $77M round | Dewpoint Therapeutics was founded because “the pharma industry has kind of been fighting with one arm behind its back,” the company's CEO Amir Nashat said, citing his colleague Mark Murcko. The company emerged in 2018 in both Cambridge, Mas... |
| 29.09.2020 | Dewpoint Therapeutics to put 'pedal to the metal' with $77M round | Dewpoint Therapeutics was founded because “the pharma industry has kind of been fighting with one arm behind its back,” the company's CEO Amir Nashat said, citing his colleague Mark Murcko. Sponsored by Agilent Technologies How would you li... |
| 29.09.2020 | Dewpoint Therapeutics Raises $77M Series B | Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B financing. The round was led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco C... |